Daniel P. Petrylak, MD, is professor of medicine (medical oncology) and professor
of urology at Yale School of Medicine and co-director of the Signal Transduction
Research Program at Yale Cancer Center.
Dr Petrylak is involved in clinical trials research on a local, national, and
international level. He is the head of the advanced bladder subcommittee in
the Southwest Oncology Group Genitourinary Committee.
Dr Petrylak served as principal investigator (PI) or co-PI on 7 Southwest Oncology
Group protocols. Most notably, he served as the PI for a randomized
trial comparing docetaxel and estramustine with mitoxantrone and prednisone
in men with hormone-refractory prostate cancer. This trial was 1 of 2
studies that demonstrated a survival benefit for docetaxel-based therapy in
men with advanced prostate cancer and resulted in the FDA’s approval of
docetaxel for hormone-refractory prostate cancer.
He also helped to design and served as PI for the SPARC trial, an international
registration trial evaluating the activity of satraplatin as a second-line
therapy for hormone-refractory prostate cancer.
Dr Petrylak has served on the program committee for the American Urological
Association (2003-2011) and the American Society of Clinical Oncology
(1995-1997; 2001-2003). He has served as a committee member for the
Immunology Devices Panel of the FDA. He has published extensively in the New
England Journal of Medicine, the Journal of Clinical Oncology, the Journal of the
National Cancer Institute, Cancer Research, and Clinical Cancer Research.